Skip to main content

Dmitry Samarsky, Kreatech


People in the News

Dmitry Samarsky has recently been named director of technology development at Dharmacon.

Previously, Samarsky was with Invitrogen, where he formulated partnership models and helped develop platform solutions for the drug discovery process, according to Dhamacon. Before that, he was with Sequitur, which was acquired by Invitrogen in late 2003 (see ).

Samarsky holds a PhD from the University of Massachusetts, Amherst.


Products & Services

Kreatech said this week that it has released the small RNA labeling kit.

According to the company, the kit uses ULS labeling technology to directly label any and all sizes of naturally occurring nucleic acids, including microRNAs and siRNAs, without the need of enzymes.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.